Physician profile
Denzil Etienne
NPI 1124389382
$8,051.79
in general payments reported to CMS, 2019-2025
29 companies · $2,935 in 2025
The $2,935 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $285 · 2020: $235 · 2021: $437 · 2022: $1,443 · 2023: $1,601 · 2024: $1,116 · 2025: $2,935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,746 · Travel and Lodging: $1,768 · Education: $138.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,746.42 |
| Travel and Lodging | $1,767.70 |
| Education | $137.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,380.23 | 2019-2025 | |
| Boston Scientific Corporation | $2,052.93 | 2019-2025 | Spyglass, General - Therapies |
| Gilead Sciences, INC. | $528.66 | 2021-2025 | Epclusa |
| Janssen Biotech, INC. | $421.57 | 2022-2025 | Tremfya, Simponi Aria, Remicade |
| Madrigal Pharmaceuticals | $378.34 | 2024-2025 | Rezdiffra, Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $179.92 | 2022-2025 | Eohilia, Entyvio, Gattex |
| Daiichi Sankyo INC. | $172.41 | 2019-2024 | Injectafer |
| Fujifilm Healthcare Americas Corporation | $100.81 | 2024 | Fujifilm |
| Celltrion USA INC. | $95.98 | 2024-2025 | Zymfentra, Vegzelma |
| Astrazeneca Pharmaceuticals Lp | $83.63 | 2023 | |
| Celgene Corporation | $81.46 | 2023-2024 | Zeposia |
| Redhill Biopharma INC. | $63.79 | 2023-2024 | Talicia |
| Olympus America INC. | $50.85 | 2021-2024 | Evis Exera III Colonovideoscope, Gastrointestinal Videoscope |
| Braintree Laboratories, INC. | $49.55 | 2023-2024 | Sutab, Suflave |
| Cook Medical LLC | $48.35 | 2021-2023 | Hemospray |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Steris Corporation | $45.56 | 2020 | |
| Pfizer INC. | $36.74 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.10 | 2024 | Cyltezo |
| Micro-Tech Endoscopy USA, INC. | $33.05 | 2024 | Lockado, Eyemax |
| W. L. Gore & Associates, INC. | $25.03 | 2022 | |
| Shire North American Group INC | $24.44 | 2019 | |
| Aimmune Therapeutics, INC. | $23.68 | 2023 | |
| Covidien Lp | $23.41 | 2019 | |
| Nestle Healthcare Nutrition INC. | $23.23 | 2022 | |
| Capsovision, INC. | $21.54 | 2023 | Capsocam Plus |
| Intra-Sana Laboratories | $19.05 | 2024 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Merck Sharp & Dohme LLC | $18.70 | 2021 | |
| Echosens North America, INC. | $17.53 | 2019 | |
| Alcresta Therapeutics, INC. | $17.25 | 2023 | Relizorb |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Denzil Etienne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.